Breast Cancer

Combination approach better targets breast cancer tumors with PIK3CA gene mutations.

Combination therapy may help combat treatment resistance in cancer patients.

ASN003 is a drug that targets cancers driven by BRAF and PI3K.

Certain hypertension drugs block breast and pancreatic cancer invasion.

Top oncology articles of 2016 on Specialty Pharmacy Times.

New cancer-spreading protein discovered in groundbreaking study.

Breast cancer patients with many social ties have significantly lower rates of death and recurrence.

Patients share their personal stories with Specialty Pharmacy Times.

Metastasis affects as many as 5% of cancer patients around the world.

Cyclin-dependent kinase inhibitor reduces Ki67 expression and shows promise in breast cancer treatment.

Ceritinib (Zykadia) could potentially be used as a first-line treatment in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.

Celgene will continue trials with Abraxane plus immunotherapy drugs.

Celgene will continue trials with Abraxane plus immunotherapy drugs.

Alcohol could cause 7100 annual cancer deaths by 2035.

Research suggests cancer cells may evade treatment by eating adult stem cells.

TIP60 levels could serve as a prognostic marker of breast cancer progression.

The new method makes breast imaging less risky, and can lessen false-positive readings.

About 1 in 6 women diagnosed with breast cancer have a symptom other than a lump.

Women who display non-lump breast cancer symptoms are less likely to seek needed care.

Determining the contents of extracellular vesicles may create targeted treatments.

Tailored dose-dense chemotherapy did not statistically improve recurrence-free survival in breast cancer patients.

Targeting a certain antioxidant protein reduces the aggressiveness of triple-negative breast cancer and increases its sensitivity to conventional anti-cancer drugs.

Promising data on pediatric relapsed/refractory acute lymphoblastic leukemia to be presented.

Ibrance has received approval from the European Commission to treat metastatic breast cancer.

A 2-year study will examine the effectiveness of advanced MRI to determine response to breast cancer treatment.